7OE8 image
Entry Detail
PDB ID:
7OE8
Keywords:
NUCLEAR PROTEIN
Title:
C-TERMINAL BROMODOMAIN OF HUMAN BRD2 WITH N5-((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-yl)-3-(1H-indol-4-yl)-N7-methyl-2,3-dihydrobenzofuran-5,7-dicarboxamide
Biological Source:
Source Organism:
Homo sapiens
Host Organism:
Escherichia coli
PDB Version:
Deposition Date:
2021-05-02
Release Date:
2021-07-28
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
1.30 Å
R-Value Free:
0.21
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 21 21 2
7OE8 validation report
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Description:Bromodomain-containing protein 2
Chain IDs:A
Chain Length:115
Number of Molecules:1
Biological Source:Homo sapiens
UniProt ID:P25440 Pfam ID:PF00439
Ligand Molecules
EDO
V9Q
Primary Citation
Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors.
J.Med.Chem. 64 10711 10741 (2021)
PMID: 34260229 DOI: 10.1021/acs.jmedchem.1c00344

Abstact

Herein, a series of 2,3-dihydrobenzofurans have been developed as highly potent bromo and extra-terminal domain (BET) inhibitors with 1000-fold selectivity for the second bromodomain (BD2) over the first bromodomain (BD1). Investment in the development of two orthogonal synthetic routes delivered inhibitors that were potent and selective but had raised in vitro clearance and suboptimal solubility. Insertion of a quaternary center into the 2,3-dihydrobenzofuran core blocked a key site of metabolism and improved the solubility. This led to the development of inhibitor 71 (GSK852): a potent, 1000-fold-selective, highly soluble compound with good in vivo rat and dog pharmacokinetics.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
7OE8